CYP2C8 and peripheral neuropathy: Meta-analyses and large patient cohorts, primarily involving breast or gynecological cancer patients treated with paclitaxel or docetaxel, indicate an increased risk of chemotherapy-induced peripheral neuropathy (CIPN) associated with CYP2C8, particularly of grade ≥2 or ≥3 severity [29,30].